(Total Views: 490)
Posted On: 08/06/2019 5:03:43 PM
Post# of 155004
Thank you for the response. A couple of follow up thoughts, though you may not have this info:
- Was this patient selected solely because of type of her cancer profile, or in addition to type, she had a very limited life expectancy (hence FDA takes the risk into approval)? If so, any guess on the amount of time she might have, i.e. w/o the Leronlimab treatment?
- Do patients like her have other collateral damage that stopping the cancer spreading may still not be sufficient to extend her life? That is, if a patient is very late stage, can other causes overwhelm the clarity of the test results?
Sad questions but trying to determine the range of outcomes. Thanks!
- Was this patient selected solely because of type of her cancer profile, or in addition to type, she had a very limited life expectancy (hence FDA takes the risk into approval)? If so, any guess on the amount of time she might have, i.e. w/o the Leronlimab treatment?
- Do patients like her have other collateral damage that stopping the cancer spreading may still not be sufficient to extend her life? That is, if a patient is very late stage, can other causes overwhelm the clarity of the test results?
Sad questions but trying to determine the range of outcomes. Thanks!
(0)
(0)
